Viral Vectors Capabilities Updates
-
Lonza Capabilities Update September 2026: Viral Vectors
10/8/2026
Bingnan Gu, Head of Viral Vector R&D, shares how the company is helping developers turn complex in vivo LVV designs into clinical-ready products, and see the new analytics that reveal what’s really inside your vector.
-
4BaseBio Capabilities Update September 2026: Viral Vectors
10/8/2026
Cell-free synthetic DNA templates can match or exceed plasmid-derived AAV titers while using less DNA, and they remove backbone sequences that plasmid-based production can package into the capsid.
-
Vector Biomed Capabilities Update September 2026: Viral Vectors
10/5/2026
Advanced lentiviral vector platforms accelerate cell and gene therapy development, improving product quality, reducing costs, and enabling efficient scale-up from discovery to GMP manufacturing.
-
Andelyn Capabilities Update September 2026: Viral Vectors
10/5/2026
Successful bioprocess technology transfer relies on effective knowledge sharing, supply chain readiness, analytical method transfer, and quality oversight to reduce risk and support scale-up.
-
Viralgen Capabilities Update September 2026: Viral Vectors
10/1/2026
Standardized AAV manufacturing platforms accelerate gene therapy development from concept to IND, reducing risk, simplifying processes, and supporting efficient scale-up.